The Impact of Commonly Prescribed Medications on Gut Bacteria
Understanding Gastrointestinal Bacterial Diversity
The influence of antibiotics on gut bacteria is well-documented, yet the effects of other commonly prescribed medications remain less understood. Recent research emphasizes the need to explore how various medications impact the bacterial diversity within the human gastrointestinal tract. While studies have primarily focused on antibiotics—known to adversely affect gut bacteria—emerging evidence indicates that non-antibiotic drugs may also play a significant role.
Study Overview and Methodology
A recent study published in *Nature Communications* by researchers from the University of Groningen sheds light on this topic. The research team utilized genomic sequencing of fecal samples to analyze the gut microbiome across three distinct participant groups: the general population, patients with irritable bowel syndrome (IBS), and those with inflammatory bowel disease (IBD). These conditions were selected due to their known effects on gut biodiversity.
The study involved 1,883 individuals, with 1,126 participants using at least one medication at the time of sampling. Participants were prescribed between 0 to 12 different medications. The researchers measured gut bacteria diversity using the Shannon Index and initially compared each medication’s effects on overall gut composition.
Findings on Individual Medications
The analysis revealed that proton-pump inhibitors (PPIs) were the only medication linked to altered bacterial composition across all three cohorts. Following this, the team conducted a meta-analysis to pool data and assess potential associations while controlling for variables such as age, sex, and BMI. This analysis identified 154 associations between specific bacterial species and individual medications, encompassing 17 drug groups. Notably, PPIs, metformin, laxatives, and vitamin D supplements exhibited the strongest associations.
Changes in certain bacterial species were also observed in relation to specific medications. For instance, the use of selective serotonin reuptake inhibitors (SSRIs) correlated with increased levels of Eubacterium Ramulus. The same group of medications (laxatives, metformin, and PPIs) continued to show significant associations when examining combinations of drugs.
Variations Among Patient Cohorts
The researchers further investigated whether responses to medications varied among the different cohorts. In the IBD group, medications like benzodiazepines, levothyroxine, and tricyclic antidepressants were associated with higher levels of specific bacterial strains. Similarly, in IBS patients, steroid inhalers were linked to increased abundance of two particular species.
Given the significant impact of PPIs, the microbiome profile of PPI users was analyzed. Even considering the influence of other medications, PPIs were found to alter the levels of 24 bacterial populations.
Exploring the Resistome
The final analysis focused on the resistome, which includes antibiotic resistance genes within the gut microbiome. The findings indicated that PPI and metformin users exhibited higher levels of antibiotic resistance genes, with PPI use particularly associated with increases in three specific genes.
Implications for Health and Future Research
This research is vital as it explores the connections between gut microflora and various health conditions, including IBS and rheumatoid arthritis. Additionally, it may explain individual variations in drug responses and side effects. For instance, the study suggests that oral steroids are linked to increased levels of Methanobrevibacter smithii, a bacterium associated with obesity and elevated BMI, which aligns with the common side effect of weight gain among oral steroid users.
The medications identified as influencing gut bacteria—laxatives, vitamin D supplements, and PPIs—are frequently prescribed and typically considered benign regarding interactions and side effects. However, this study underscores that even these medications can induce changes in gut biodiversity, potentially affecting overall health and the metabolism of other drugs.
Limitations and Future Directions
The study acknowledges several limitations. While numerous associations between gut bacteria and medications were identified, causation cannot be established due to unaccounted variables. In participants with altered gut microbiomes, it remains challenging to discern whether these changes stem from medications or underlying diseases. Nonetheless, this research opens the door to a captivating area that warrants further investigation.
Reference
Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications. 2020;11(1):362.